GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (FRA:PCJ) » Definitions » Cyclically Adjusted Price-to-FCF

Abeona Therapeutics (FRA:PCJ) Cyclically Adjusted Price-to-FCF : (As of May. 26, 2024)


View and export this data going back to 1980. Start your Free Trial

What is Abeona Therapeutics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Abeona Therapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Abeona Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abeona Therapeutics Cyclically Adjusted Price-to-FCF Chart

Abeona Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Abeona Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Abeona Therapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Abeona Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abeona Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Abeona Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Abeona Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Abeona Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Abeona Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.514/131.7762*131.7762
=-0.514

Current CPI (Mar. 2024) = 131.7762.

Abeona Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -8.571 100.560 -11.232
201409 -5.190 100.428 -6.810
201412 -1.120 99.070 -1.490
201503 -3.668 99.621 -4.852
201506 -1.625 100.684 -2.127
201509 -1.778 100.392 -2.334
201512 -2.200 99.792 -2.905
201603 -1.880 100.470 -2.466
201606 -2.201 101.688 -2.852
201609 -2.769 101.861 -3.582
201612 -2.132 101.863 -2.758
201703 -3.444 102.862 -4.412
201706 -2.758 103.349 -3.517
201709 -3.554 104.136 -4.497
201712 -2.661 104.011 -3.371
201803 -3.268 105.290 -4.090
201806 -5.629 106.317 -6.977
201809 -4.794 106.507 -5.931
201812 -12.777 105.998 -15.884
201903 -7.523 107.251 -9.243
201906 -8.798 108.070 -10.728
201909 -8.761 108.329 -10.657
201912 -3.866 108.420 -4.699
202003 -3.358 108.902 -4.063
202006 -2.402 108.767 -2.910
202009 -2.512 109.815 -3.014
202012 -0.363 109.897 -0.435
202103 -3.127 111.754 -3.687
202106 -2.479 114.631 -2.850
202109 -2.326 115.734 -2.648
202112 -7.075 117.630 -7.926
202203 -2.161 121.301 -2.348
202206 -1.468 125.017 -1.547
202209 -1.069 125.227 -1.125
202212 -0.747 125.222 -0.786
202303 -0.661 127.348 -0.684
202306 -0.528 128.729 -0.540
202309 -0.219 129.860 -0.222
202312 -0.331 129.419 -0.337
202403 -0.514 131.776 -0.514

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Abeona Therapeutics  (FRA:PCJ) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Abeona Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Abeona Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Abeona Therapeutics (FRA:PCJ) Business Description

Industry
Traded in Other Exchanges
Address
1330 Avenue of the Americas, 33rd Floor, New York, NY, USA, 10019
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its lead clinical programs consist of EB-101, autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, adeno-associated virus-based gene therapy for Sanfilippo syndrome type A, and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B.

Abeona Therapeutics (FRA:PCJ) Headlines

No Headlines